drugset / Trial / NCT01581658

Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes

NCT01581658

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to assess the effect of the different degrees of renal impairment on the pharmacokinetics, pharmacodynamics and safety of BI10773 following oral administration of high dose BI10773 as a single dose in Japanese patients with type 2 diabetes mellitus.

Timeline

Start
2012-04-01
Primary completion
2012-11-01
Completion
2012-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 25 mg Oral